Advertisement
Interested parties may access the call by dialing +1-877-941-4778 fromwithin the United States, or +1-480-629-9763 if calling internationally. Theconference ID is 4345891. It is advisable to dial in approximately 5-10minutes prior to the start of the call.
Advertisement
A playback will be available through August 24, 2010. To listen, pleasecall 1-877-870-5176 within the United States or 1-858-384-5517 when callinginternationally. Utilize the pass code 4345891 for the replay.
This call is being web cast by ViaVid Broadcasting and can be accessed atViaVid's website at http://www.viavid.net or at the following link:http://viavid.net/dce.aspx?sid=00007973 . To access the web cast, you willneed to have the Windows Media Player on your desktop. For the free downloadof the Media Player please visit:http://www.microsoft.com/windows/windowsmedia/en/download/default.asp .
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiaries inChina, develops, manufactures and markets pharmaceutical products for avariety of diseases and conditions. The Company's most popular product is itsXin-Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine forchronic hepatitis B, a disease affecting approximately 10% of the Chinesepopulation. In addition to its hepatitis product, Biostar currentlymanufactures two broad-based OTC products, two prescription-basedpharmaceuticals, one medical device, and four health products. The Company hasadopted international standards, holds one patent and is in the process ofapplying for two patents.
Safe Harbor
Certain statements in this release concerning our future growth prospectsare forward-looking statements, within the meaning of Section 27A of the U.S.Securities Act of 1933, as amended, and Section 21E of the U.S. SecuritiesExchange Act of 1934, as amended, which involve a number of risks anduncertainties that could cause actual results to differ materially from thosein such forward-looking statements. The risks and uncertainties relating tothese statements include, but are not limited to, risks and uncertaintiesregarding the success of our investments, risks and uncertainties regardingfluctuations in earnings, our ability to sustain our previous levels ofprofitability including on account of our ability to manage growth, intensecompetition, wage increases in China, our ability to attract and retain highlyskilled professionals, time and cost overruns on fixed-price, fixed-time framecontracts, client concentration, our ability to successfully complete andintegrate potential acquisitions, withdrawal of governmental fiscal incentives,political instability and regional conflicts and legal restrictions on raisingcapital or acquiring companies outside China. Additional risks that couldaffect our future operating results are more fully described in our UnitedStates Securities and Exchange Commission filings including our S-1 dated June27, 2008, our 10-K for the year ended December 31, 2009, and other recentfilings. These filings are available at http://www.sec.gov . We may, from timeto time, make additional written and oral forward-looking statements,including statements contained in our filings with the Securities and ExchangeCommission and our reports to shareholders. We do not undertake to update anyforward-looking statements that may be made from time to time by or on ourbehalf.For further information, please contact: Company: Mr. Deyin "Bill" Chen, CFO Tel: +86-138-1610-0700 Email: [email protected] Investor Relations: HC International, Inc. (US) Ted Haberfield, Executive VP Tel: +1-760-755-2716 Email: [email protected] HC International, Inc. (Shanghai, China) Feng Peng, SVP China: +86-138-122-71616 Email: [email protected]
SOURCE Biostar Pharmaceuticals, Inc.
